Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment
Cell therapy is an emerging strategy for precision treatment of scleroderma. This review systematically summarizes the research progress of mesenchymal stem cell (MSC) and chimeric antigen receptor T cell (CAR-T) therapies in scleroderma and discusses the challenges and future directions for develop...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1530887/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527922002755584 |
|---|---|
| author | Liting Chen Rongshan Huang Chaoshuo Huang Guiming Nong Yuanyuan Mo Lvyin Ye Kunhong Lin Anping Chen Anping Chen |
| author_facet | Liting Chen Rongshan Huang Chaoshuo Huang Guiming Nong Yuanyuan Mo Lvyin Ye Kunhong Lin Anping Chen Anping Chen |
| author_sort | Liting Chen |
| collection | DOAJ |
| description | Cell therapy is an emerging strategy for precision treatment of scleroderma. This review systematically summarizes the research progress of mesenchymal stem cell (MSC) and chimeric antigen receptor T cell (CAR-T) therapies in scleroderma and discusses the challenges and future directions for development. MSCs possess multiple functions, including immunomodulation, anti-fibrosis, and promotion of vascular regeneration, all of which can improve multiple pathological processes associated with scleroderma. Studies have demonstrated that MSCs can alleviate skin fibrosis by inhibiting CCL2 production and reducing the recruitment of pathological macrophages; their paracrine effects can exert extensive regulatory functions. CAR-T cell therapy ca specifically target and eliminate autoreactive immune cells, exhibiting enhanced specificity and personalized potential. Different cell therapies may have complementary and synergistic effects in treating scleroderma, such as MSCs exerting their effects through paracrine mechanisms while CAR-T cells specifically eliminate pathological cells. Furthermore, cell-free therapies derived from MSCs, such as extracellular vesicles or exosomes, may help circumvent the limitations of MSC therapy. Although cell therapy has opened new avenues for the precision treatment of scleroderma, it still faces numerous challenges. In the future, it is essential to strengthen integration of basic and clinical research, establish standardized protocols for cell preparation and quality control, develop personalized treatment plans, and rationally combine cell therapy with existing treatment methods to maximize its advantages and improve patient prognosis and quality of life. |
| format | Article |
| id | doaj-art-aff33b4ec63445fc9336d8d8d68f6370 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-aff33b4ec63445fc9336d8d8d68f63702025-01-15T05:11:09ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.15308871530887Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatmentLiting Chen0Rongshan Huang1Chaoshuo Huang2Guiming Nong3Yuanyuan Mo4Lvyin Ye5Kunhong Lin6Anping Chen7Anping Chen8Department of Rheumatology and Immunology, Qinzhou First People's Hospital, Qinzhou, Guangxi, ChinaDepartment of Rheumatology and Immunology, Qinzhou First People's Hospital, Qinzhou, Guangxi, ChinaDepartment of Rheumatology and Immunology, Qinzhou First People's Hospital, Qinzhou, Guangxi, ChinaDepartment of Rheumatology and Immunology, Qinzhou First People's Hospital, Qinzhou, Guangxi, ChinaDepartment of Rheumatology and Immunology, Qinzhou First People's Hospital, Qinzhou, Guangxi, ChinaDepartment of Rheumatology and Immunology, Qinzhou First People's Hospital, Qinzhou, Guangxi, ChinaDepartment of Rheumatology and Immunology, Qinzhou First People's Hospital, Qinzhou, Guangxi, ChinaDepartment of Rheumatology and Immunology, Qinzhou First People's Hospital, Qinzhou, Guangxi, ChinaMinda Hospital of Hubei Minzu University, Enshi, ChinaCell therapy is an emerging strategy for precision treatment of scleroderma. This review systematically summarizes the research progress of mesenchymal stem cell (MSC) and chimeric antigen receptor T cell (CAR-T) therapies in scleroderma and discusses the challenges and future directions for development. MSCs possess multiple functions, including immunomodulation, anti-fibrosis, and promotion of vascular regeneration, all of which can improve multiple pathological processes associated with scleroderma. Studies have demonstrated that MSCs can alleviate skin fibrosis by inhibiting CCL2 production and reducing the recruitment of pathological macrophages; their paracrine effects can exert extensive regulatory functions. CAR-T cell therapy ca specifically target and eliminate autoreactive immune cells, exhibiting enhanced specificity and personalized potential. Different cell therapies may have complementary and synergistic effects in treating scleroderma, such as MSCs exerting their effects through paracrine mechanisms while CAR-T cells specifically eliminate pathological cells. Furthermore, cell-free therapies derived from MSCs, such as extracellular vesicles or exosomes, may help circumvent the limitations of MSC therapy. Although cell therapy has opened new avenues for the precision treatment of scleroderma, it still faces numerous challenges. In the future, it is essential to strengthen integration of basic and clinical research, establish standardized protocols for cell preparation and quality control, develop personalized treatment plans, and rationally combine cell therapy with existing treatment methods to maximize its advantages and improve patient prognosis and quality of life.https://www.frontiersin.org/articles/10.3389/fmed.2024.1530887/fullsclerodermacell therapymesenchymal stem cellsmesenchymal stem cell exosomeschimeric antigen receptor T cells |
| spellingShingle | Liting Chen Rongshan Huang Chaoshuo Huang Guiming Nong Yuanyuan Mo Lvyin Ye Kunhong Lin Anping Chen Anping Chen Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment Frontiers in Medicine scleroderma cell therapy mesenchymal stem cells mesenchymal stem cell exosomes chimeric antigen receptor T cells |
| title | Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment |
| title_full | Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment |
| title_fullStr | Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment |
| title_full_unstemmed | Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment |
| title_short | Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment |
| title_sort | cell therapy for scleroderma progress in mesenchymal stem cells and car t treatment |
| topic | scleroderma cell therapy mesenchymal stem cells mesenchymal stem cell exosomes chimeric antigen receptor T cells |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1530887/full |
| work_keys_str_mv | AT litingchen celltherapyforsclerodermaprogressinmesenchymalstemcellsandcarttreatment AT rongshanhuang celltherapyforsclerodermaprogressinmesenchymalstemcellsandcarttreatment AT chaoshuohuang celltherapyforsclerodermaprogressinmesenchymalstemcellsandcarttreatment AT guimingnong celltherapyforsclerodermaprogressinmesenchymalstemcellsandcarttreatment AT yuanyuanmo celltherapyforsclerodermaprogressinmesenchymalstemcellsandcarttreatment AT lvyinye celltherapyforsclerodermaprogressinmesenchymalstemcellsandcarttreatment AT kunhonglin celltherapyforsclerodermaprogressinmesenchymalstemcellsandcarttreatment AT anpingchen celltherapyforsclerodermaprogressinmesenchymalstemcellsandcarttreatment AT anpingchen celltherapyforsclerodermaprogressinmesenchymalstemcellsandcarttreatment |